(CIDRAP News) – A US Food and Drug Administration (FDA) panel today recommended that the agency approve the nation's first H5N1 influenza vaccine, despite new evidence that the vaccine is less protective than reported in a clinical trial last year.
(CIDRAP News) The US Food and Drug Administration (FDA) today approved the nation's first H5N1 influenza vaccine, made by Sanofi Pasteur, which federal officials hope will buy some time to develop a more precisely targeted vaccine if the virus evolves into a pandemic strain.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) – China's State Food and Drug Administration (SFDA) yesterday approved the country's first prepandemic H5N1 influenza vaccine, an inactivated whole-virus product made by Sinovac, a Beijing-based biotechnology company.
(CIDRAP News) – The US Department of Health and Human Services (HHS) has accepted the first batch of H5N1 avian influenza vaccine based on the H5N1 variant known as clade 2.2, which has spread most widely across Asia, Europe, and Africa.
(CIDRAP News) In a progress report on federal pandemic influenza planning efforts, the US Department of Health and Human Services (HHS) says several companies working under federal contracts are on track to develop cell culturebased pandemic flu vaccines.
(CIDRAP News) The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.
(CIDRAP News) Large trials in three countriesthe United States, Hungary, and Chinarecently confirmed the safety and efficacy of H1N1 vaccines, yielding new insights on how to best use vaccines in a pandemic setting.